Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

BLPH stock opened at $0.01 on Friday. The business’s fifty day moving average price is $0.03 and its two-hundred day moving average price is $0.04. The stock has a market capitalization of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.02.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.